Barr Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Barr Pharmaceuticals
Type Subsidiary
Industry Pharmaceuticals & Medical Devices
Founded New York (1970)
Headquarters Montvale, NJ,
Key people Bruce Downey, CEO
Products Generic and Proprietary Pharmaceuticals
Revenue Over $1 Billion in FY 2005
Employees 2000
Parent Teva Pharmaceutical Industries
Website www.tevapharm.com

Barr Pharmaceuticals was a global specialty pharmaceutical company that operated in more than 30 countries worldwide. Barr was engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals, and active pharmaceutical ingredients.

History[edit]

Barr Laboratories Inc. was founded in 1970 by Stanley Benerofe and Edwin A. Cohen and was ultimately taken public under their leadership.

On July 18, 2008; it was announced that rival firm, Teva Pharmaceutical Industries Ltd. would acquire Barr Pharmaceuticals Inc. for $7.46 billion plus the assumption of net debt of approximately $1.5 billion.[1] Today Barr Laboratories exists only as a sub-division of Teva Pharmaceuticals, as part of the Teva Active Pharmaceutical Ingredients (TAPI) division.

Teva Pharmaceuticals develops and markets generic pharmaceuticals under various brand names, including the Barr Laboratories, Inc. label. Teva Pharmaceuticals is the largest generic drug manufacturer in the world.

References[edit]

  1. ^ Staff (2008-07-21), Teva Coughs Up $7.46B for Barr Reinforcing Its Number One Spot in the Generics Market, Genetic Engineering & Biotechnology News, GEN News Highlights (Mary Ann Liebert), ISSN 1937-8661, retrieved 2008-09-26